Allegheny Financial Group LTD purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,698 shares of the company’s stock, valued at approximately $224,000. Several other hedge funds and other institutional investors have also […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price upped by Canaccord Genuity Group from $154.00 to $164.00 in a research note issued to investors on Thursday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. NBIX has been the subject of a number of other reports. Barclays upped their […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Citigroup from $140.00 to $150.00 in a research report released on Friday, Benzinga reports. The firm currently has a neutral rating on the stock. Other analysts also recently issued research reports about the company. Oppenheimer raised their price objective on Neurocrine Biosciences from […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Oppenheimer from $200.00 to $216.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities analysts have also weighed in on the company. Wells Fargo & Company upgraded Neurocrine […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by Oppenheimer from $200.00 to $216.00 in a research note issued to investors on Thursday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock. Other equities research analysts have also issued reports about the company. Citigroup reduced their price objective on […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target raised by stock analysts at BMO Capital Markets from $129.00 to $138.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ price target would suggest a potential downside of 1.93% from […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $200.00 to $216.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 53.51% from the stock’s previous close. […]
Certuity LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the fourth quarter, HoldingsChannel reports. The fund purchased 3,150 shares of the company’s stock, valued at approximately $415,000. Several other institutional investors and hedge funds have also bought and sold shares of the stock. Headinvest LLC purchased a new stake […]
Intrust Bank NA lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 18.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,977 shares of the company’s stock after selling 686 shares during the quarter. Intrust Bank […]
Certuity LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,150 shares of the company’s stock, valued at approximately $415,000. A number of other hedge funds also recently modified their […]